No Data
No Data
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Express News | Zhifei Biological Products Says Board Elects Jiang Rensheng as Chairman
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
Chongqing Zhifei Biological Products Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Zhifei Biotech: 2024 Semi-Annual Report
Zhifei Biotech: 2024 Semi-Annual Report Summary